Eupraxia to Present Phase 1b/2 EP-104GI 36-Week Trial Data at Digestive Disease Week
Eupraxia Pharmaceuticals will present four abstracts on EP-104GI from its Phase 1b/2 RESOLVE trial for eosinophilic esophagitis at Digestive Disease Week in Chicago May 2-5, highlighting persistent histological and endoscopic improvements over 36 weeks. Company hosts virtual investor event May 4 to discuss EP-104GI’s potential to prevent esophageal strictures.
1. Presentation Schedule
Eupraxia will present four abstracts at Digestive Disease Week in Chicago from May 2 to 5, 2026, including one oral session on May 3 and three poster sessions on May 5. Presentations will cover dose escalation, histological improvements, endoscopic outcomes and durability of dysphagia relief over 36 weeks.
2. EP-104GI Trial Highlights
The Phase 1b/2 RESOLVE trial evaluates escalating doses of EP-104GI, a long-acting submucosal corticosteroid, showing persistent reductions in eosinophilic inflammation and fibrosis and sustained symptom relief across multiple dose cohorts.
3. Virtual Investor Event
On May 4 at 8am ET, company management and key opinion leaders will discuss EP-104GI’s mechanism for preventing esophageal strictures, definition and prevalence of recurrent strictures, and its potential to reduce intervention frequency.
4. Diffusphere™ Technology Platform
Eupraxia’s Diffusphere™ delivers targeted, extended-release drug therapy directly into esophageal tissue to maximize local efficacy and minimize systemic exposure, with applications beyond eosinophilic esophagitis in inflammation, oncology and infectious disease.